ストックスクリーナーアプリを入手
2.565
6.88%
-0.195
Maxcyte Inc (MXCT) 最新ニュース
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges - Investing.com UK
MaxCyte Expands Capital with New Stock Issuance - TipRanks
MaxCyte stock plunges to 52-week low, touches $2.75 - Investing.com
MaxCyte CFO completes RSU vesting and tax-related sale By Investing.com - Investing.com Australia
MaxCyte CFO completes RSU vesting and tax-related sale - Investing.com India
MaxCyte Announces CFO’s RSU Vesting and Share Sale - TipRanks
MaxCyte Announces Change in Major Shareholder Voting Rights - TipRanks
BlackRock Increases Stake in MaxCyte to 7.87% - TipRanks
MaxCyte executives receive equity incentives By Investing.com - Investing.com South Africa
MaxCyte executives receive equity incentives - Investing.com India
MaxCyte Awards Stock Options and Units to Executives - TipRanks
Maxcyte CFO Douglas Swirsky sells $22,061 in common stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock - Investing.com India
Maxcyte general counsel David Sandoval sells $1,122 in stock - Investing.com
Maxcyte CFO Douglas Swirsky sells $22,061 in common stock - Investing.com
BlackRock Increases Stake in MaxCyte to 7.71% - TipRanks
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha
What is William Blair’s Estimate for MaxCyte Q1 Earnings? - Defense World
US Bancorp DE Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
Stifel Nicolaus Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - Defense World
MaxCyte files annual report with SEC By Investing.com - Investing.com Australia
MaxCyte core business revenue grows despite overall decline By Investing.com - Investing.com Australia
Stifel cuts MaxCyte stock price target to $9 from $11 By Investing.com - Investing.com Australia
Stifel cuts MaxCyte stock price target to $9 from $11 - Investing.com
MaxCyte stock touches 52-week low at $3.11 amid market challenges By Investing.com - Investing.com South Africa
MaxCyte stock touches 52-week low at $3.11 amid market challenges - Investing.com Australia
MaxCyte’s Promising Financial Outlook and Strategic Growth Justify Buy Rating - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2024 Earnings Call Transcript - Insider Monkey
MaxCyte price target lowered to $6 from $8 at BTIG - TipRanks
MaxCyte stock price target cut to $6 at BTIG By Investing.com - Investing.com South Africa
MaxCyte price target lowered to $9 from $11 at Stifel - TipRanks
MaxCyte stock price target cut to $6 at BTIG - Investing.com India
MaxCyte files annual report with SEC - Investing.com India
MaxCyte core business revenue grows despite overall decline - Investing.com India
Maxcyte Sees 2025 Core Revenue To Grow 8% To 15% - Marketscreener.com
MaxCyte reports a return to core revenue growth in FY24 - DirectorsTalk Interviews
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates By Investing.com - Investing.com Australia
MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MaxCyte’s Strategic Expansion and Financial Resilience Drive Buy Rating - TipRanks
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates - Investing.com India
0.62%
0.92%
大文字化:
|
ボリューム (24 時間):